CARDIOMETABOLIC DEVELOPMENT MECHANISMS OBESITY SYNDROME

Authors

  • Kravchenko N. A. GU "Institute of Therapy them. L. T. Malaya Namne Ukraine, Kharkov
  • Klimenko N. N. Harkov National Medical University

DOI:

https://doi.org/10.21856/j-PEP.2012.1.11

Keywords:

Cardiometabolic development mechanisms Obesity syndrome

Abstract

Cardiometabolic development mechanisms Obesity syndrome

References

Bloomgarden, Z. T. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease [Text] / Z. T. Bloomgarden // Diabetes Care. — 2005. — Vol. 28. — P. 1518–1523.

Kim, C. H. Younossi. Nonalcoholic fatty liver disease: A manifestation of the metabolic Syndrome [Text] / C. H. Kim, M. Zobair // Clev. Clinic. J. Med. — 2008. — Vol. 75, № 10. — P. 721–728.

Machado, M. Non-alcoholic fatty liver disease and insulin resistance [Text] / M. Machado, H. CortezPinto // Europ. J. Gastroent. Hepatol. — 2005. — Vol. 17. — P. 823–826.

Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease [Text] / G. Targher, L. Bertolini, R. Padovani [et al.] // Diabetes Care. — 2006. — Vol. 29. — P. 1325–1330.

Relationship of liver enzymes to insulin sensitivity and intra-abdominal fat [Text] / T. M. Wallace, K. M. Utzsecneider, G. Tong [et al.] // Diabetes Care. — 2007. — Vol. 30. — P. 2673–2678.

Ahima, R. S. Adipose tissue as an endocrine organ [Text] / R. S. Ahima, J. S. Flier // Trends. Endocrin. Metabol. — 2000. –Vol. 11. — P. 327–332.

Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes [Text] / A. Guilherme, J. V. Virbasius, V. Puri, M. P. Czech // Nat. Rev. Mol. Cell. Biol. — 2008. — Vol. 9. — P. 367–377.

Hajer, G. T. W. van Haeften. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases [Text] / G. T.W. Hajer van Haeften, F. L. J. Visseren // Europ. Heart. J. — 2008. — Vol. 29. — P. 2959–2971.

Relationship between adipocyte size and adipokine expression and secretion [Text] / T. Skurk, C. Alberti-Huber, C. Herder, H. Hauner // J. Clin. Endocrinol. Metabol. — 2007. — Vol. 92. — P. 1023–1033.

Macrophage secreted factors impairs human adipogenesis: involvement of proinflammatory state in preadipocytes [Text] / D. Lacasa, S. Taleb, M. Keophiphath [et al.] // Endocrinology. — 2007. — Vol. 148. — P. 868–877.

Permana, P. A. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance [Text] / P. A. Permana, C. Menge, P. D. Reaven // Biochem. Biophys. Res. Commun. — 2006. — Vol. 341. — P. 507–514.

Adipose tissue dysfunction in obesity, diabetes, and vascular diseases [Text] / R. Gideon Hajer, W. Timon van Haeften, L. J. Frank Visseren // Europ. Heart. J. — 2008. — Vol. 29. — P. 2959–2971.

Expression of tumor necrosis factor (TNF)-alpha protein in the subcutaneous and visceral adipose tissue in correlation with adipocyte cell volume, serum TNF-alpha, soluble serum TNF-receptor-2 concentrations and C-peptide level [Text] / G. Winkler, S. Kiss, L. Keszthelyi [et al.] // Europ. J. Endocrinol. — 2003. — Vol. 149. — P. 129–135.

Mineralcorticoid receptor antagonism attenuates kidney renin-angiotensin-aldosterone system mediated filtration barrier remodeling in the transgenic Ren2 rat [Text] / A. Whaley-Connell, J. Habibi, Y. Wei [et al.] // Am. J. Physiol. — Renal. Physiol. — 2009. — Vol. 296, № 5. — P. F1013–22.

Esteve, E. Adipocytokines and Insulin Resistance The possible role of lipocalin-2, retinol binding protein-4, and adiponectin [Text] / E. Esteve, W. Ricart, J. Manuel Fern Andez-Real // Diabetes Care. — 2009. — Vol. 32, Suppl. 2. — P. 5362–5367.

Kashyap, S. The insulin resistance syndrome: physiological considerations [Text] / S. Kashyap, R. Defronzo // Diabetes Vasc. Dis. Res. — 2007. — Vol. 4. — P. 13–19.

Aldosterone-receptor antagonism in hypertension [Text] / P. M. Jansen, A. H. Danser, B. P. Imholz, A. H. van den Meiracker // J. Hypertens. — 2009. — Vol. 27, № 4. — P. 680–91.

An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fi-brosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells [Text] / N. Kurikawa, M. Suga, S. Kuroda [et al.] // British. J. Pharmacol. — 2003. — Vol. 139. — P. 1085–1094.

Skurk, T. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kB [Text] / T. Skurk, van V. Harmelen, H. Hauner // Arterioscler. Thromb. Vasc. Biol. — 2004. — Vol. 24. — P. 1199–1203.

Brown, N. J. Aldosterone and vascular inflammation [Text] / N. J. Brown // Hypertension. — 2008. — Vol. 51. — P. 161–167.

Angiotensin II as a trophic factor of white adipose tissue: Stimulation of adipose cell formation [Text] / P. Saint-Marc, L. P. Kozak, G. Ailhaud [et al.] // Endocrinology. — 2001. — Vol. 142. — P. 487–492.

Sharma, A. M. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? [Text] / A. M. Sharma // Int. J. Biochem. — 2003. — Vol. 35. — P. 807–825.

Angiotensin II infusion increases hepatic triglyceride production via its type 2 receptor in rats [Text] / J. Ran, T. Hirano, M. Adachi // J. Hypertens. — 2005. — Vol. 23. — P. 1525–1530.

Sowers Aldosterone: Role in the Cardiometabolic Syndrome and Resistant Hypertension [Text] / A. Whaley-Connell, S. J. Megan, R. James // Prog. Cardiovasc. Dis. — 2010. — Vol. 52, № 5. — P. 401–409.

Prevalence and characteristics of the metabolic syndrome in primary aldosteronism [Text] / F. Fallo, F. Veglio, C. Bertello [et al.] // J. Clin. Endocrinol. Metabol. — 2006. — Vol. 91, № 2. — P. 454–9.

Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion [Text] / K. K. Gaddam, M. K. Nishizaka, M. N. PrattUbunama [et al.] // Arch. Intern. Med. — 2008. — Vol. 168, № 11. — P. 1159–1164.

Hayden, M. R. Pancreatic Renin-Angiotensin-Aldosterone System in the Cardiometabolic Syndrome and Type-2 Diabetes [Text] / M. R. Hayden, J. R. Sowers // J. Cardiometabol. Synd. — 2008. — Vol. 3. — P. 129–131.

Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O–2 and systolic blood pressure in mice [Text] / F. E. Rey, M. E. Cifuentes, A. Kiarash [et al.] // Circ. Res. — 2001. — Vol. 89. — P. 408–14.

Enhanced aldosterone signaling in the early nephrology of rats with metabolic syndrome: possible contribution of fat-derived factors [Text] / M. Nagase, S. Yoshida, S. Shibata [et al.] // J. Am. Soc. Nephrol. — 2006. — Vol. 17. — P. 3438–46.

The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension [Text] / J. R. Sowers, A. Whaley-Connell, M. Epstein // Ann. Intern. Med. — 2009. — Vol. 150, № 11. — P. 776–83.

Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferatoractivated receptor-gamma, and proinflammatory adipokines [Text] / C. Guo, V. Ricchiuti, B. Q. Lian [et al.] // Circulation. — 2008. — Vol. 117. — P. 2253–2261.

Rutkowski, B. Triple pharmacological blockade of the reninangiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial [Text] / B. Rutkowski // Am. J. Kid. Dis. — 2008. — Vol. 52, № 3. — P. 486–93.

Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance [Text] / J. Ran, T. Hirano, T. Fukui [et al.] // Metabolism. — 2006. — Vol. 55. — P. 478–488.

Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance [Text] / G. Tarantino, S. Savastano, A. Colao // World J. Gastroenterol. — 2010. — Vol. 16, № 38. — P. 4773–4783.

The Roles of Leptin and Adiponectin A Novel Paradigm in Adipocytokine Regulation of Liver Fibrosis and Stellate Cell Biology [Text] / D. Xiaokun, K. S. Neeraj, L. Songbai [et al.] // Am. J. Pathol. — 2005.– Vol. 166, № 6. — P. 1655–1679.

Adiponectin stimulates glucose utilization and fattyacid oxidation by activating AMP-activated protein kinase [Text] / T. Yamauchi, J. Kamon, Y. Minokoshi [et al.] //Nat. Med. — 2002. — Vol. 8. — P. 1288–1295.

Adipocyte determination- and differentiation-dependent factor 1 /sterol regulatory element-bonding protein 1c regulates mouse adiponectin expression [Text] / J. B. Seo, H. M. Moon, M. J. Noh [et al.] // J. Biol. Chem. — 2004. — Vol. 279. — P. 22108–221117.

Adiponectin, a key adipokine in obesity related liver diseases [Text] / C. Buechler, J. Wanninger, M. Neumeier // World J. Gastroenterol. — 2011. — Vol. 17, № 23. — P. 2801–2811.

Matsuzawa, Y. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin [Text] / Y. Matsuzawa // Gastroenterology. — 2003. — Vol. 125. — P. 1796–1807.

Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-related atherogenic and thrombogenic cardiovascular disease risk factors among men [Text] / N. F. Chu, D. Spiegelman, G. S. Hotamisligil [et al.] // Atherosclerosis. — 2001. — Vol. 157. — P. 495–503.

Bataller, R. Liver fibrosis [Text] / R. Bataller, R. Bataller, D. A. Brenner // J. Clin. Invest. — 2005. — Vol. 115. — P. 209–18.

Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats [Text] / K. Okada, T. Hirano, J. Ran, M. Adachi // Hypertens Res. — 2004. — Vol. 27. — P. 293–299.

Therapy of NAFLD, antioxidants and cytoprotective agents [Text] / C. Y. Chang, C. K. Argo, A. M. S. AlOsaimi, S. H. Caldwell // J. Clin. Gastroenterol. — 2006. — Vol. 40. — P. S51–S60.

Insulin resistance and hypertention. The insulin resistence atherosclerosis study [Text] / M. F. Saad, M. Rewers, J. Selby [et al.] // Hypertention. — 2004. — Vol. 43, № 6. — P. 1324–1331.

Semenkovich, C. F. Insulin resistance and atherosclerosis [Text] / C. F. Semenkovich // J. Clin. Invest. — 2006. — Vol. 116. — P. 1813–1822.

Goldstein, B. J. Adiponectin: A novel adipokine linking adipocytes and vascular function [Text] / B. J. Goldstein, R. Scalia // J. Clin. Endocrinol. Metabol. — 2004. — Vol. 89. — P. 2563–2568.

Local adiponectin treatment reduces atherosclerotic plaque size in rabbits [Text] / C.-J. Li, H.-W. Sun, Zhul Fa-Liang [et al.] // J. Endocrinol. — 2007. — Vol. 193. — P. 137–145.

Downloads

Published

2012-03-15

How to Cite

Kravchenko, N. A., & Klimenko, N. N. (2012). CARDIOMETABOLIC DEVELOPMENT MECHANISMS OBESITY SYNDROME. Problems of Endocrine Pathology, 39(1), 84-93. https://doi.org/10.21856/j-PEP.2012.1.11